1-11 of 11
Laura N Eadie
Close
Sort by
Journal Articles

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N Eadie, Elias Lagonik, Elyse C Page, Caitlin E Schutz, Susan L Heatley, Barbara J McClure, Michelle Olivia Forgione, PhD, David T Yeung, Timothy P Hughes, Deborah L White
Journal: Blood
Blood blood.2024024776.
https://doi.org/10.1182/blood.2024024776
Published: 2024
Includes: Supplemental data
Journal Articles

Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present

Laura N Eadie, Caitlin E Schutz, Elyse C Page, Tace S Conlin, Susan L Heatley, Elias Lagonik, Jacqueline A Rehn, David T Yeung, Timothy P Hughes, Deborah L White
Journal: Blood
Blood (2023) 142 (Supplement 1): 1602.
https://doi.org/10.1182/blood-2023-184647
Published: 2023
Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Deborah L White, Jacqueline A Rehn, Caitlin E Schutz, Susan L Heatley, Laura N Eadie, Ashlee Thomson, Elyse C Page, Michael Osborn, Shane Gangatharan, Ashley P Ng, Shaun Fleming, Pasquale Fedele, Toby Trahair, John Casey, Sally Mapp, Carol CY Cheung, Tasman Armytage, Michelle Henderson, Rosemary Sutton, Stephen Robert Larsen, Peter Presgrave, John Kwan, Samuel Bennett, Chun Yew Fong, Luciano Dalla-Pozza, David T Yeung, Matthew Greenwood
Journal: Blood
Blood (2023) 142 (Supplement 1): 1609.
https://doi.org/10.1182/blood-2023-178473
Published: 2023
Journal Articles

Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis

Susan L Heatley, Elyse C Page, Laura N Eadie, Barbara J McClure, Jacqueline Rehn, David T Yeung, Michael Philip Osborn, Tamas Revesz, Maria Kirby, Deborah L White
Journal: Blood
Blood (2021) 138 (Supplement 1): 1317.
https://doi.org/10.1182/blood-2021-150086
Published: 2021
Journal Articles

Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities

Laura N Eadie, BSc, PhD, Jacqueline Rehn, MSc(BioTech), Susan L Heatley, PhD MD, Barbara J McClure, BSc,PhD, Caitlin Schutz Schutz, BSc (Hons), James Breen, BSc,PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Rosemary Sutton, BSc MSc PhD, Deborah L White, PhDFFSc(RCPA)
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-138995
Published: 2020
Journal Articles

Persistent Activation of JAK/STAT Signaling Plays an Important Role in in Vitro Jaki Resistance in TYK2- rearranged B-Cell Acute Lymphoblastic Leukaemia

Paniz Tavakoli, Laura N Eadie, BSc, PhD, Susan L Heatley, PhD MD, John B Bruning, BSc,PhD, Deborah L White, PhDFFSc(RCPA)
Journal: Blood
Blood (2020) 136 (Supplement 1): 3.
https://doi.org/10.1182/blood-2020-139048
Published: 2020
Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)
Journal: Blood
Blood (2019) 134 (Supplement_1): 3949.
https://doi.org/10.1182/blood-2019-127788
Published: 2019
Journal Articles

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

Laura N Eadie, PhD, Jarrad M Goyne, BMedSc (Hons), Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Deborah L White, PhD FFSc (RCPA)
Journal: Blood
Blood (2016) 128 (22): 4237.
https://doi.org/10.1182/blood.V128.22.4237.4237
Published: 2016
Journal Articles

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Verity A Saunders, BSc (Hons), Jueqiong Wang, PhD, Liu Lu, PhD, Laura N Eadie, PhD, Jennifer A McLean, Jarrad M Goyne, BMedSc (Hons), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2016) 128 (22): 1121.
https://doi.org/10.1182/blood.V128.22.1121.1121
Published: 2016
Journal Articles

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Laura N Eadie, PhD, Verity A Saunders, BSc (Hons), Tamara M Leclercq, PhD, Susan Branford, PhDFFSc (RCPA), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA
Journal: Blood
Blood (2015) 126 (23): 4841.
https://doi.org/10.1182/blood.V126.23.4841.4841
Published: 2015
Journal Articles

The Clinical Significance of Early Imatinib Induced ABCB1 Overexpression in Chronic Phase CML Patients: A TIDEL II Sub-Study

Laura N Eadie, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA)
Journal: Blood
Blood (2015) 126 (23): 348.
https://doi.org/10.1182/blood.V126.23.348.348
Published: 2015